GlassScriptPhysician profile
Priscilla Lopez
NPI 1194501924
$1,881.18
in general payments reported to CMS, 2019-2025
25 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $810 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,881.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $276.51 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.94 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $165.99 | 2024-2025 | Verquvo, Capvaxive |
| Madrigal Pharmaceuticals | $159.83 | 2025 | Rezdiffra |
| Amgen INC. | $152.63 | 2024-2025 | Repatha, Otezla, Repatha |
| Boston Scientific Corporation | $136.74 | 2025 | Watchman |
| Exact Sciences Corporation | $130.19 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $120.97 | 2024-2025 | Ozempic |
| Lilly USA, LLC | $78.33 | 2024 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $72.07 | 2025 | Venaseal |
| Kiniksa Pharmaceuticals International, Plc | $69.06 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $34.62 | 2025 | Camzyos |
| Astellas Pharma US INC | $31.86 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $30.93 | 2025 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $24.69 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agepha Pharma Fz LLC | $21.85 | 2024 | Lodoco |
| Abiomed | $20.97 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $19.04 | 2024 | Farxiga |
| Corcept Therapeutics | $18.27 | 2025 | Korlym |
| Heartflow, INC. | $17.09 | 2025 | |
| Grifols USA, LLC | $16.94 | 2025 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $16.68 | 2024 | Xarelto |
| Dexcom, INC. | $16.63 | 2025 | Dexcom G6 Transmitter |
| Baxter Healthcare | $15.96 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Medicure Pharma INC. | $13.39 | 2025 | Zypitamag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priscilla Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.